Ozempic (same active ingredient, different dosing) is the covered semaglutide product for diabetes Prior authorization required for all GLP-1 agonists Step therapy requirement: must document trial and failure of metformin for at least 90 days BMI requirement: must be 27 or higher with at least one weight-related comorbidity For obesity without diabetes: Wegovy is classified as a weight-loss medication and falls under MassHealth's excluded drug categories No coverage regardless of BMI No coverage even with documented obesity-related conditions like hypertension, sleep apnea, or osteoarthritis This exclusion applies to all MassHealth plans: Standard, CarePlus, CommonHealth, and Family Assistance The policy is codified in the MassHealth Drug List updated quarterly
Combined strategically, the two are described as producing compounding effects that neither delivers alone
Of the remaining case reports and studies assessed, each found that despite well exceeding the recommended fasting guidelines, patients experienced aspiration or regurgitation of gastric contents, even after suction (Santos et al
However, with continued accumulation of A plaques, the inflammatory and neurotoxic parenchymal environment can progress to further damage the BBB (Erickson and Banks, 2013)
Perspective on the Coevolutionary Role of Host and Gut Microbiota in Polyphenol Health Effects: Metabotypes and Precision Health
Even a microscopic amount of one peptide introduced into another vial can ruin your data